Jun Ni

438 total citations
23 papers, 260 citations indexed

About

Jun Ni is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Jun Ni has authored 23 papers receiving a total of 260 indexed citations (citations by other indexed papers that have themselves been cited), including 13 papers in Oncology, 7 papers in Pulmonary and Respiratory Medicine and 6 papers in Molecular Biology. Recurrent topics in Jun Ni's work include Lung Cancer Research Studies (7 papers), Lung Cancer Treatments and Mutations (7 papers) and Cancer Immunotherapy and Biomarkers (5 papers). Jun Ni is often cited by papers focused on Lung Cancer Research Studies (7 papers), Lung Cancer Treatments and Mutations (7 papers) and Cancer Immunotherapy and Biomarkers (5 papers). Jun Ni collaborates with scholars based in China and United States. Jun Ni's co-authors include Xiaotong Zhang, Li Zhang, Xiaoyan Si, Rui Huang, Yue Tao, Shengxia Yin, Hanping Wang, Yuxin Chen, Han Shen and Chao Wu and has published in prestigious journals such as Journal of Clinical Oncology, SHILAP Revista de lepidopterología and Frontiers in Immunology.

In The Last Decade

Jun Ni

19 papers receiving 257 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Jun Ni China 10 92 88 76 46 41 23 260
Laksmi Wulandari Indonesia 10 85 0.9× 102 1.2× 49 0.6× 62 1.3× 57 1.4× 52 345
Silvia Mezzalira Italy 6 40 0.4× 76 0.9× 60 0.8× 40 0.9× 21 0.5× 8 215
Haojie Feng China 7 166 1.8× 74 0.8× 91 1.2× 44 1.0× 22 0.5× 9 320
Qiaoqiao Huang China 9 69 0.8× 26 0.3× 150 2.0× 107 2.3× 14 0.3× 12 280
Eleni Lagkadinou Germany 8 85 0.9× 68 0.8× 71 0.9× 15 0.3× 14 0.3× 16 193
Ellen Araj United States 7 168 1.8× 25 0.3× 42 0.6× 29 0.6× 15 0.4× 14 256
Angelika Valentin Austria 7 111 1.2× 49 0.6× 37 0.5× 19 0.4× 125 3.0× 12 313
Shengxia Yin China 11 197 2.1× 43 0.5× 70 0.9× 10 0.2× 144 3.5× 36 464
Zongxing Yang China 12 87 0.9× 27 0.3× 79 1.0× 60 1.3× 139 3.4× 33 323
Dominick Leone United States 12 50 0.5× 114 1.3× 68 0.9× 10 0.2× 62 1.5× 21 283

Countries citing papers authored by Jun Ni

Since Specialization
Citations

This map shows the geographic impact of Jun Ni's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Jun Ni with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Jun Ni more than expected).

Fields of papers citing papers by Jun Ni

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Jun Ni. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Jun Ni. The network helps show where Jun Ni may publish in the future.

Co-authorship network of co-authors of Jun Ni

This figure shows the co-authorship network connecting the top 25 collaborators of Jun Ni. A scholar is included among the top collaborators of Jun Ni based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Jun Ni. Jun Ni is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Su, Ya, Jiayu Fu, Feifan Xu, et al.. (2025). Circulating proteomic biomarkers for cerebral amyloid angiopathy screening and risk stratification. Alzheimer s & Dementia. 21(3). e70044–e70044.
2.
Wang, Xue, Wei Wu, Di Zhang, et al.. (2025). Prevalence of cerebral amyloid angiopathy and its correlation with Alzheimer's disease and cognition in an autopsy‐confirmed cohort from China. Alzheimer s & Dementia Diagnosis Assessment & Disease Monitoring. 17(2). e70100–e70100.
3.
Chen, Yuxin, Tiantian Zhao, Lin Chen, et al.. (2024). SARS-CoV-2 Omicron infection augments the magnitude and durability of systemic and mucosal immunity in triple-dose CoronaVac recipients. mBio. 15(4). e0240723–e0240723. 5 indexed citations
4.
Li, Ye, Yi Lv, Jianping Li, et al.. (2024). Dexamethasone relieves the inflammatory response caused by inguinal hernia meshes through miR-155. Hernia. 28(4). 1113–1119. 1 indexed citations
5.
Ni, Jun, Xiaoyan Si, Hanping Wang, Xiaotong Zhang, & Li Zhang. (2023). Camrelizumab plus platinum-irinotecan followed by maintenance camrelizumab plus apatinib in untreated extensive-stage small-cell lung cancer: a nonrandomized clinical trial. Frontiers in Immunology. 14. 1168879–1168879. 12 indexed citations
6.
Miao, Kang, Shuangni Yu, Jun Ni, Xiaotong Zhang, & Li Zhang. (2022). Second primary tumor after immune checkpoint inhibitor therapy: A case report. Thoracic Cancer. 13(7). 1076–1078. 6 indexed citations
7.
Ni, Jun, Xiaoyan Si, Hanping Wang, Xiaotong Zhang, & Li Zhang. (2022). Prognostic biomarkers and immune cell infiltration characteristics in small cell lung cancer. SHILAP Revista de lepidopterología. 1(1). 18–24. 3 indexed citations
8.
Miao, Kang, Xiaotong Zhang, Hanping Wang, et al.. (2022). Real-World Data of Different Immune Checkpoint Inhibitors for Non-Small Cell Lung Cancer in China. Frontiers in Oncology. 12. 859938–859938. 17 indexed citations
9.
Chen, Yuxin, Lin Chen, Shengxia Yin, et al.. (2022). The Third dose of CoronVac vaccination induces broad and potent adaptive immune responses that recognize SARS-CoV-2 Delta and Omicron variants. Emerging Microbes & Infections. 11(1). 1524–1536. 37 indexed citations
10.
11.
Ni, Jun, Xiaotong Zhang, Hanping Wang, et al.. (2021). Clinical characteristics and prognostic model for extensive‐stage small cell lung cancer: A retrospective study over an 8‐year period. Thoracic Cancer. 13(4). 539–548. 9 indexed citations
12.
Ni, Jun, Xiaoyan Si, & Li Zhang. (2021). Non‐small‐cell lung cancer with ERBB2 mutation in non‐tyrosine kinase domain benefits from pyrotinib: A case report. Thoracic Cancer. 12(8). 1244–1247. 4 indexed citations
13.
Ni, Jun, et al.. (2021). Silencing of circHIPK3 Sensitizes Paclitaxel-Resistant Breast Cancer Cells to Chemotherapy by Regulating HK2 Through Targeting miR-1286. Cancer Management and Research. Volume 13. 5573–5585. 28 indexed citations
14.
Chen, Yuxin, Shengxia Yin, Xin Tong, et al.. (2021). Dynamic SARS-CoV-2-specific B-cell and T-cell responses following immunization with an inactivated COVID-19 vaccine. Clinical Microbiology and Infection. 28(3). 410–418. 52 indexed citations
15.
Liu, Xiaoqin, et al.. (2021). Albumin‐to‐alkaline phosphatase ratio: A novel prognostic index for patients with driver mutation‐negative advanced non‐small cell lung cancer. The Clinical Respiratory Journal. 15(5). 540–549. 5 indexed citations
16.
Ni, Jun, Han‐Ping Wang, Xiaoyan Si, et al.. (2020). Treatment with or without bevacizumab as a first‐line and maintenance therapy for advanced non‐squamous non‐small cell lung cancer: A retrospective study. Thoracic Cancer. 11(7). 1869–1875. 2 indexed citations
17.
18.
Si, Xiaoyan, Peng Song, Jun Ni, et al.. (2020). Management of immune checkpoint inhibitor‐related adverse events: A review of case reports. Thoracic Cancer. 11(3). 498–504. 14 indexed citations
19.
Wang, Jian, Jun Ni, Zhigang Zhou, et al.. (2019). <p>Shanghai Parents’ Perception And Attitude Towards The Use Of Antibiotics On Children: A Cross-Sectional Study</p>. Infection and Drug Resistance. Volume 12. 3259–3267. 22 indexed citations
20.
Ni, Jun, et al.. (2018). Overexpression of CLEC3A promotes tumor progression and poor prognosis in breast invasive ductal cancer. OncoTargets and Therapy. Volume 11. 3303–3312. 21 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Laksmi Wulandari Breakdown of academic impact, for papers by Silvia Mezzalira Breakdown of academic impact, for papers by Haojie Feng Breakdown of academic impact, for papers by Qiaoqiao Huang Breakdown of academic impact, for papers by Eleni Lagkadinou Breakdown of academic impact, for papers by Ellen Araj Breakdown of academic impact, for papers by Angelika Valentin Breakdown of academic impact, for papers by Shengxia Yin Breakdown of academic impact, for papers by Zongxing Yang Breakdown of academic impact, for papers by Dominick Leone
Rankless by CCL
2026